Zydus Lifesciences Limited has announced the launch of Aerolife Mini™, a groundbreaking respiratory care device that represents India's first portable and foldable spacer for asthma and COPD patients. The innovation-led life-sciences company introduced this next-generation pMDI (pressurised Metered-Dose Inhaler) enhancer aimed at enhancing drug delivery and patient adherence, under an exclusive licensing arrangement with AeroDel Technology Innovations Pvt. Ltd.

Revolutionary Design Addresses Critical Healthcare Challenge

India faces a significant burden of chronic respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis, driven by rising air pollution, smoking, recurrent infections, and delayed diagnosis. Millions of patients depend on long-term inhaled therapy to control symptoms and maintain quality of life.

Enhanced Drug Delivery and Patient Adherence Features

Aerolife Mini™ addresses the limitations of conventional spacer devices, which are typically characterized by bulky form factors that limit daily portability. Traditional spacers require repeated assembly, increasing the risk of incorrect use and low real-world adherence, particularly outside the home.

The new device introduces several breakthrough features specifically designed to enhance drug delivery and patient adherence:

Strategic Partnership and Technology Innovation

This initiative aligns with Zydus' long-term strategy of building innovation-led, sustainable, and differentiated respiratory franchises through patient-centric drug devices. The launch marks a significant step in the company's approach to drive drug device led innovation in respiratory care.

About the Companies

Zydus Lifesciences Ltd. operates with the overarching purpose of empowering people with freedom to live healthier and more fulfilled lives. The global lifesciences company discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions.

AeroDel Technology Innovations Pvt. Ltd. develops and manufactures patient-centric respiratory devices designed for scale and affordability, focusing on improving access to care in India and other global markets. The company is supported by Venture Center, the Department of Science and Technology Government of India, AIC-CCMB, and the Startup India Seed Fund.

Zydus Lifesciences has significantly expanded its semaglutide market presence through strategic partnerships with leading pharmaceutical companies. The company has now formalized comprehensive co-marketing agreements with both Lupin Limited and Torrent Pharmaceuticals Limited to maximize patient reach through diverse distribution networks and brand portfolios across India's diabetes and weight management treatment sectors.

Enhanced Multi-Partner Strategy

Zydus has implemented a comprehensive multi-partner approach for semaglutide commercialization, establishing agreements with Lupin Limited and most recently with Torrent Pharma on March 18, 2026. These partnerships create extensive market coverage, leveraging each partner's unique strengths and distribution capabilities to enhance patient access across different market segments.

Comprehensive Brand Portfolio Distribution

The multi-partner strategy establishes distinct brand portfolios across all collaborating companies. Under the Torrent agreement, Zydus will manufacture and supply the product while Torrent Pharma receives semi-exclusive rights to co-market in India. As part of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus.

Innovation and Patient-Centric Approach

Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable patient-friendly pen device. The formulation enables delivery of all strengths for both indications through a single device platform, designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance.

Therapeutic Applications and Market Access

The semaglutide injection addresses critical therapeutic needs across India's healthcare market. The product serves adults with insufficiently controlled type 2 diabetes mellitus as monotherapy when metformin is inappropriate, or in combination with other diabetes medications. Additionally, it functions as adjunct therapy for chronic weight management in adults with BMI of 30.00 kg/m² or greater, or 27.00 kg/m² or greater with weight-related comorbid conditions including hypertension, type 2 diabetes, or dyslipidemia.

Through these strategic partnerships, Zydus combines strong product development and manufacturing capabilities with partners' deep market expertise, significantly expanding patient access to advanced GLP-1 therapies for metabolic disorders across India's diverse healthcare landscape.

Source: Company/INE010B01027/9a41d337-6456-45d6-b12b-0b2a302117c9.pdf